Health Care & Life Sciences » Biotechnology | Ampliphi Biosciences Corp.

Ampliphi Biosciences Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
55,861.00
23,109.00
516.00
18,838.00
12,838.00
Depreciation, Depletion & Amortization
82.00
158.00
330.00
369.00
374.00
Other Funds
-
-
-
173.00
-
Funds from Operations
7,391.00
12,016.00
9,623.00
11,259.00
8,735.00
Changes in Working Capital
1,053.00
556.00
158.00
653.00
457.00
Net Operating Cash Flow
6,338.00
12,572.00
9,781.00
10,606.00
9,192.00
Capital Expenditures
102.00
1,202.00
210.00
279.00
58.00
Net Investing Cash Flow
102.00
1,202.00
210.00
279.00
58.00
Cash Dividends Paid - Total
-
-
-
80.00
-
Issuance/Reduction of Debt, Net
2,000.00
-
-
100.00
815.00
Net Financing Cash Flow
25,892.00
-
12,780.00
7,226.00
8,671.00
Net Change in Cash
19,493.00
13,774.00
2,789.00
3,659.00
579.00
Free Cash Flow
6,440.00
13,774.00
9,991.00
10,885.00
9,250.00
Deferred Taxes & Investment Tax Credit
-
-
73.00
556.00
1,302.00
Change in Capital Stock
23,892.00
-
12,780.00
7,579.00
9,486.00
Exchange Rate Effect
41.00
-
-
-
-

About Ampliphi Biosciences

View Profile
Address
3579 Valley Centre Drive
San Diego California 92130
United States
Employees -
Website http://www.ampliphibio.com
Updated 09/14/2018
AmpliPhi Biosciences Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company was founded in March 1989 and is headquartered in San Diego, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.